• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • EGFR Inhibitor
    4 Drugs classified under this drug class

    All the Drug Class Drugs

    Caprelsa 100 mg
    partial basket chart
    Caprelsa 100 mg

    EGFR Inhibitor, Kinase Inhibitor. Vandetanib 100 mg.
    FC TABS: 30 x 100mg. Recom.
    dose 300mg 1x dly. Pts. must be given
    patient alert card and be informed of
    risks Assess QTc interval prior to init.
    tmt. Can reduce dosage if necess.
    See lit.
    Tmt. aggressive and sympt. medullary
    thyroid cancer (MTC) in pts. with
    unresectable locally advanced or
    metastatic dis. Pts.in whom Rearranged
    during Transfection (RET) mutation is not
    known or is neg., a possible lower benefit
    should be taken into account. See lit.
    C/I: Hypersens. to active subst. or excip;
    congenital long QTc syndrome; pts. with
    QTc interval > 480msec.; concomit. use
    of arsenic, cisapride,erythromycin, iv.
    toremifene, mizolastine moxifloxacin,
    class Ia and III antiarrhythmics. See lit.

    partial basket chart

    EGFR Inhibitor, Monoclonal Antibody. Cetuximab 5 mg/ml.
    VIAL (I.V. infus.): 10 ml, 20 ml, 50 ml, 100
    ml. Initial: 400 mg/m2, foll. by 1 x wkly
    dose: 250 mg/m2.
    Dosage must be individ. adjust.
    according to pt. med. cond.
    Tmt. of pts. with (EGFR)-expressing, RAS
    wild-type metast. colorectal canc. incomb.
    with irinotecan-based chemot., in 1st -line
    in comb. with FOLFOX, as a single agent
    in pts. who have failed oxaliplatinand
    irinotecan- based ther. and whoare
    intoler. to irinotecan. Tmt. of pts. With
    squamous cell canc. of the head and neck
    (SCCHN), in comb. with rad. ther.forlocal.
    advanced dis., in comb. With platinumbased
    chemo. for recur. and/or metast.
    dis., as a single agent after fail. of
    platinum-based chemo. for recur.and/or
    metast. dis.
    C/I: Severe hypersens, The comb. With
    oxaliplatin-cont. chemot. is contraindic.
    for pts. with mutant RAS metast.
    colorectal canc. (mCRC) or for whom
    RAS mCRC status is unknown.
    Contraind. for concom. used chemot.
    agents or rad. therapy must be
    considered before init. of comb. tmt.

    Gefitinib Teva
    partial basket chart
    Gefitinib Teva

    EGFR Inhibitor. Gefitinib 250 mg.
    F.C. TAB.:30. 250 mg (1 tab.)×1/d with / without food. See lit.
    Tmt. of  adult pts. with local. advanced or metastat. Non‐small cell lung cancer (NSCLC) with activat. mutations of EGFR‐TK.
    C/I: Hypersens.


    Astra Zeneca
    partial basket chart

    EGFR Inhibitor. Gefitinib 250 mg.
    F.C. TABS: 30. Swall. whole 1 tab dly, with/
    out food, as monother. in advanced
    non-small-cell lung cancer (NSCLC)
    prev. receiv. tmt. with cytotox.
    chemother. Not recommend. child/
    adolesc. No adjust reqd. in pt. age,
    bdy. wt., gender, ethnicity, ren. funct.
    Poorly tol. diarrh./skin adverse drug reacts: Brief (up to 14 days) ther.
    interrupt foll. by reinstate 250 mg
    Tmt. local advanced/metastat. NSCLC
    who have prev. received chemother.
    C/I: Hypersens.